EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Cytokine Dynamics in Bortezomib‐Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans

Nadine Cebulla iD, Daniel Schirmer, Eva Runau, Leon Flamm, Calvin Terhorst, Laura Jähnel, Johanna Güse, Nicola Giordani, Annett Wieser, Felicitas Schoch, Marie-Luise Reinle, Sonja Gommersbach und 7 weitere

Journal of the Peripheral Nervous System · 2026

DOI: 10.1111/jns.70090 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the Peripheral Nervous System, 2026. Verfasst von Nadine Cebulla und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Würzburg, Germany. Hauptthemen laut MEDLINE: Bortezomib, Peripheral Nervous System Diseases, Multiple Myeloma, Antineoplastic Agents. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KFO5001 ResolvePAIN, funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project ID: 426503586., Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Bortezomib‐induced peripheral neuropathy (BIPN) remains a common treatment side effect in patients with multiple myeloma (MM). Data from rodent models indicate a role of proinflammatory cytokines in BIPN pathophysiology, making them potential therapeutic targets. We therefore tested cytokine levels throughout the course of BIPN in a cohort of MM patients.

Methods

We performed an interim analysis of a monocentric, non‐randomized, observational study including 113 patients with MM. Three groups of patients—within their first cycle of BTZ treatment (FC), with ongoing BTZ treatment at the time of recruiting (OT), and with BTZ treatment in the past (PT)—were compared to controls. Sixteen FC patients were followed up for a median of 6 months. Serum TNF‐α, IL‐6, and CCL2, the cytokines most often implied in the animal models, were analyzed via the ELLA device.

Results

CCL2 levels were not different among our patient groups or in comparison with healthy controls. Compared to healthy controls, the FC group had the highest IL‐6 levels, followed by the PT and then the OT group. The FC group also had higher TNF‐α levels compared to all other groups. Six months after inclusion, patients showed a decrease in TNF‐α levels compared to their baseline. There was no correlation between TNF‐α levels and neuropathy severity or impairment in daily life.

Interpretation

Factors related to MM may influence systemic cytokine levels in BIPN patients, limiting conclusions on their role in BIPN pathophysiology and their utility as drug targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BortezomibPeripheral Nervous System DiseasesMultiple MyelomaAntineoplastic AgentsCytokinesTumor Necrosis Factor-alphaChemokine CCL2HumansMaleFemaleMiddle AgedAgedInterleukin-6Adult

Stichwörter der Autor:innen

CIPNbortezomibbortezomib‐induced peripheral neuropathychemokinescytokines

Substanzen

BortezomibAntineoplastic AgentsCytokinesTumor Necrosis Factor-alphaInterleukin-6Chemokine CCL2CCL2 protein, human

Autor:innen und Institutionen

  • Department of Neurology, University Hospital Würzburg, Germany.
  • Department of Internal Medicine II, University Hospital Würzburg, Germany.
  • Centre for Interdisciplinary Pain Medicine, Department of Anesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Würzburg, Germany.

ORCID-Profile: Nadine Cebulla, Xiang Zhou, Claudia Sommer

Förderung

  • KFO5001 ResolvePAIN, funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project ID: 426503586.
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Cebulla, N., Schirmer, D., Runau, E., Flamm, L., Terhorst, C., Jähnel, L., Güse, J., Giordani, N., Wieser, A., Schoch, F., Reinle, M. L., Gommersbach, S., Papagianni, A., Zhou, X., Einsele, H., Reinhold, A. K., Rittner, H., Kortüm, K. M., & Sommer, C. (2026). Cytokine Dynamics in Bortezomib‐Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.70090

Vancouver

Cebulla N, Schirmer D, Runau E, Flamm L, Terhorst C, Jähnel L, et al. Cytokine Dynamics in Bortezomib‐Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans. Journal of the Peripheral Nervous System. 2026. doi:10.1111/jns.70090

BibTeX
@article{Cebulla2026,
  author = {Cebulla, Nadine and Schirmer, Daniel and Runau, Eva and Flamm, Leon and Terhorst, Calvin and Jähnel, Laura and Güse, Johanna and Giordani, Nicola and Wieser, Annett and Schoch, Felicitas and Reinle, Marie-Luise and Gommersbach, Sonja and Papagianni, Aikaterini and Zhou, Xiang and Einsele, Hermann and Reinhold, Ann-Kristin and Rittner, Heike and Kortüm, K Martin and Sommer, Claudia},
  title = {Cytokine Dynamics in Bortezomib‐Induced Peripheral Neuropathy: Challenges in Translating Preclinical Findings to Humans},
  journal = {Journal of the Peripheral Nervous System},
  year = {2026},
  doi = {10.1111/jns.70090}
}
Kostenlos starten →